Overview
Immuto Scientific provides an AI-enabled, high-throughput platform combining mass spectrometry and machine learning for structural surfaceomics analysis, identifying novel disease-specific protein conformations (SPCs) as therapeutic targets, particularly for cancer. The company offers contract research services to support drug discovery against undruggable targets, including patented Plasma-Induced Modification of Biomolecules (PLIMB) technology for assessing drug-target binding. They collaborate with institutions like UW-Madison on colorectal cancer target discovery and advance an internal pipeline of biologics and ADCs for indications such as AML, solid tumors, and NSCLC.
Frequently asked questions
- What core technology does Immuto Scientific offer for drug discovery?
- Immuto's patented AI-assisted mass spectrometry platform, including PLIMB technology, enables high-throughput characterization of disease surfaceomes to identify novel epitopes and surface protein conformations (SPCs) at ~100 structures per week.
- What services are available for pharmaceutical R&D?
- As a contract research organization, Immuto provides analytical research services for target discovery, structural proteomics, and drug binding optimization, focused on cancer and undruggable targets.
- What is Immuto's therapeutic focus and pipeline?
- Immuto targets cancer with programs like IMTO 4842 (AML, ADC), IMTO 5727 (solid tumors, biologic), and IMTO 3437 (TKI-resistant NSCLC, biologic), leveraging their structural platform for precision therapies.